Steatotic Liver Disease: Causes, Risk Factors & Prevention
New Study Redefines Fatty Liver Disease Subtypes, Highlighting Metabolic and Lifestyle Factors
Table of Contents
Odense, Denmark – A groundbreaking study published in the Journal of Hepatology has redefined the landscape of fatty liver disease, introducing a new classification system that categorizes patients into three distinct subgroups: metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD). The research, led by Camilla Dalby Hansen at Odense University Hospital, underscores the important impact of metabolic health, genetics, and lifestyle on the prevalence and severity of steatotic liver disease (SLD).
Understanding the New SLD Subtypes
The study evaluated steatosis through liver histology, a gold standard for assessing liver health. Based on these findings, three SLD subgroups were defined:
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Characterized by the presence of liver steatosis, at least one cardiometabolic risk factor (such as obesity, diabetes, hypertension, or dyslipidemia), and low alcohol intake.
Metabolic and Alcohol-Related Liver Disease (MetALD): Defined by the presence of liver steatosis, at least one cardiometabolic risk factor, and moderate alcohol intake.
Alcohol-Related Liver Disease (ALD): Encompasses individuals with high alcohol intake in the absence of cardiometabolic risk factors, or very heavy alcohol intake irrespective of cardiometabolic risk.
Key Findings: Prevalence and Disease Severity
The study revealed that a considerable 70% of participants had SLD, with MASLD being the most prevalent subtype, accounting for 51% of cases. MetALD was identified in 13% of participants, and ALD in 6.3%. Notably, the research found that more participants in the metabolic cohort exhibited SLD compared to the alcohol cohort, emphasizing the growing role of metabolic health in liver disease.
When examining disease severity, participants with ALD demonstrated the most advanced liver damage. 25% of individuals with ALD showed liver stiffness measurement (LSM) values of 8 kPa or higher, compared to 12% in the MASLD group and a similar proportion in the MetALD group. Furthermore,8% of participants in the ALD group had advanced fibrosis,substantially higher than the 2.8% and 2.6% observed in the MASLD and MetALD groups, respectively. This highlights that while metabolic factors contribute significantly to SLD, alcohol remains a potent driver of severe liver disease.
Risk Factors and protective Elements
The research identified several key factors influencing the development of liver steatosis:
Cardiometabolic Risk Factors: All assessed cardiometabolic risk factors were found to increase the odds of liver steatosis. High waist circumference emerged as the strongest risk factor, with an odds ratio of 6.65 (95% CI, 5.36-8.25), indicating a substantial link between abdominal obesity and fatty liver.
Genetic Predisposition: Two specific genetic risk alleles were identified as significant determinants of liver steatosis, suggesting a genetic component to the disease.
Protective Factors: Conversely, higher levels of education and increased physical activity were associated with decreased odds of liver steatosis. This underscores the importance of lifestyle interventions in preventing and managing fatty liver disease.* Insulin Resistance: The study pinpointed insulin resistance as the most prominent risk factor for elevated liver stiffness, reinforcing the critical link between metabolic health and liver fibrosis.
Implications for Primary Care
The authors emphasize that the interplay of social determinants of health, genetic predisposition, and lifestyle choices significantly influences the prevalence of SLD. This necessitates a nuanced management approach in primary care, with a particular focus on addressing health inequalities through preventive care initiatives. Understanding these distinct subtypes allows for more targeted interventions and personalized patient care.
Study Limitations and future Directions
While this study provides valuable insights, it acknowledges certain limitations. The electronic invitation-based recruitment method may have introduced selection bias, potentially limiting the generalizability of findings to the broader population. The single-center design and predominantly White participant demographic also restrict its applicability to other ethnic and cultural groups. Due to the absence of long-term follow-up, prognostic differences among the newly defined SLD subclasses could not be definitively established. Future research should aim to validate these findings in diverse populations and explore the long-term outcomes associated with each SLD subtype.
Disclosures
This study received funding from the Novo nordisk Foundation for the DECIDE project and MicrobLiver, the European Union’s Horizon